Lantheus Holdings, Inc. $LNTH Shares Purchased by Sector Gamma AS

Sector Gamma AS grew its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 28.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 64,403 shares of the medical equipment provider’s stock after acquiring an additional 14,102 shares during the quarter. Sector Gamma AS’s holdings in Lantheus were worth $3,303,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Park Avenue Securities LLC increased its stake in Lantheus by 6.7% during the 2nd quarter. Park Avenue Securities LLC now owns 2,841 shares of the medical equipment provider’s stock valued at $233,000 after buying an additional 179 shares during the period. Parkside Financial Bank & Trust lifted its position in Lantheus by 20.2% in the second quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock worth $103,000 after purchasing an additional 212 shares during the period. First National Advisers LLC lifted its position in Lantheus by 0.8% in the second quarter. First National Advisers LLC now owns 27,995 shares of the medical equipment provider’s stock worth $2,292,000 after purchasing an additional 213 shares during the period. State of New Jersey Common Pension Fund D boosted its stake in Lantheus by 1.0% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 25,197 shares of the medical equipment provider’s stock valued at $2,063,000 after purchasing an additional 249 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new position in shares of Lantheus during the 2nd quarter valued at $26,000. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on LNTH shares. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. Truist Financial boosted their price target on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Mizuho upped their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Trading Up 0.5%

Shares of NASDAQ LNTH opened at $67.51 on Friday. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.29. The company has a market cap of $4.48 billion, a price-to-earnings ratio of 28.37 and a beta of -0.11. The business has a fifty day simple moving average of $63.52 and a 200-day simple moving average of $60.42.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.27. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The firm had revenue of $384.01 million for the quarter, compared to the consensus estimate of $363.42 million. During the same quarter in the previous year, the company earned $1.70 EPS. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. Sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.